Aurobindo Pharma receives USFDA Approval for Norethindrone Acetate Tablets

11 Jan 2016 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Norethindrone Acetate Tablets USP, 5mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Aygestin Tablets, 5 mg, of Duramed Pharmaceuticals.

Norethindrone Acetate Tablet is used in the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels and secondary amenorrhea. The approved product has an estimated market size of $24 million for the twelve months ending November 2015 according to IMS.

This is the 57th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. The company now has a total of 230 ANDA approvals (199 Final approvals including 10 from Aurolife Pharma LLC and 31 Tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×